A study has found uneven access to biologics for patients with psoriasis. The study's findings are part of a broader discussion on psoriasis treatment, which includes the development of prediction models for relapse risk and the impact of new therapies on patient outcomes. The research suggests that access to certain treatments may be inconsistent, but the specifics of the issue and its effects are still being explored.